Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP421672.RAS-ske0V-UOl-W20G8iemM1sbvEG4_kuIUq0g_G9zC1w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP421672.RAS-ske0V-UOl-W20G8iemM1sbvEG4_kuIUq0g_G9zC1w130_assertion type Assertion NP421672.RAS-ske0V-UOl-W20G8iemM1sbvEG4_kuIUq0g_G9zC1w130_head.
- NP421672.RAS-ske0V-UOl-W20G8iemM1sbvEG4_kuIUq0g_G9zC1w130_assertion description "[For the current standard treatment with pegylated interferon alfa and ribavirin in patients with chronic hepatitis C, infection with HCV genotypes 2 and 3, baseline viral load below 400,000-800,000 IU/ml, Asian and Caucasian ethnicity, younger age, low GGT levels, absence of advanced fibrosis/cirrhosis, and absence of steatosis in the liver have been identified as independent pretreatment predictors of a sustained virologic response.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP421672.RAS-ske0V-UOl-W20G8iemM1sbvEG4_kuIUq0g_G9zC1w130_provenance.
- NP421672.RAS-ske0V-UOl-W20G8iemM1sbvEG4_kuIUq0g_G9zC1w130_assertion evidence source_evidence_literature NP421672.RAS-ske0V-UOl-W20G8iemM1sbvEG4_kuIUq0g_G9zC1w130_provenance.
- NP421672.RAS-ske0V-UOl-W20G8iemM1sbvEG4_kuIUq0g_G9zC1w130_assertion SIO_000772 18715665 NP421672.RAS-ske0V-UOl-W20G8iemM1sbvEG4_kuIUq0g_G9zC1w130_provenance.
- NP421672.RAS-ske0V-UOl-W20G8iemM1sbvEG4_kuIUq0g_G9zC1w130_assertion wasDerivedFrom befree-20140225 NP421672.RAS-ske0V-UOl-W20G8iemM1sbvEG4_kuIUq0g_G9zC1w130_provenance.
- NP421672.RAS-ske0V-UOl-W20G8iemM1sbvEG4_kuIUq0g_G9zC1w130_assertion wasGeneratedBy ECO_0000203 NP421672.RAS-ske0V-UOl-W20G8iemM1sbvEG4_kuIUq0g_G9zC1w130_provenance.